Evidence map›Paper›PMID 30885956›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2019

Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease Lethality.

Govindarajan Thangavelu, Yu-Chi Lee, Michael Loschi, K Melanie Schaechter, Colby J Feser, Brent H Koehn, Elizabeth C Nowak, Robert Zeiser, Jonathan S Serody, William J Murphy and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 3 countries.

Govindarajan ThangaveluDivision of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455.
Yu-Chi LeeDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Norris Cotton Cancer Center, Lebanon, NH 03756.ORCID 0000-0003-0038-7869
Michael LoschiDivision of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455.
K Melanie SchaechterDivision of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455.ORCID 0000-0001-9362-205X
Colby J FeserDivision of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455.ORCID 0000-0001-5971-9085
Brent H KoehnDivision of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455.
Elizabeth C NowakDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Norris Cotton Cancer Center, Lebanon, NH 03756.
Robert ZeiserDepartment of Hematology, Oncology and Stem Cell Transplantation, University Medical Center, Albert Ludwig University of Freiburg, 79106 Freiburg, Germany.
Jonathan S SerodyLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 79106.
William J MurphyDepartment of Dermatology, Center for Comparative Medicine, University of California, Davis School of Medicine, Sacramento, CA 95817.
David H MunnDepartment of Pediatrics, Georgia Health Sciences University, Augusta, GA 30912; and.
Pierre ChambonInstitut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS UMR7104, INSERM U964, 67404 Illkirch Cedex, France.
Randolph J NoelleDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Norris Cotton Cancer Center, Lebanon, NH 03756.
Bruce R BlazarDivision of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455; blaza001@umn.edu.ORCID 0000-0002-9608-9841
University of Minnesota · USDartmouth College · USAugusta University Health · USCentre National de la Recherche Scientifique · FRUniversity of California Davis Medical Center · USUniversity of Freiburg · DEUniversity of North Carolina at Chapel Hill · US

Funding

Transplant Tolerance in Non-Human PrimatesU19AI051731 · NIAID · UNIVERSITY OF WESTERN ONTARIO · PI LARSEN, CHRISTIAN P. · 2002 to 2022
$54.1M
Novel Biologic Therapies for GVHDR01HL095791 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI KEAN, LESLIE S · 2010 to 2025
$13.3M
Enhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7M
IN VIVO PREVENTION OF MURINE GVHDR01AI034495 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1993 to 2016
$6.2M
Reprogramming the TME for immunogenic antigen-presentationR01CA103320 · NCI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI MUNN, DAVID H. · 2003 to 2024
$6.0M
T-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4M
In Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4M
T CELL TARGETING FOR GVHDR37HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R. · 1998 to 2007
$3.2M
Mechanistic Evaluations of ILC2 Cells for the Treatment/Prevention of GVHDR01HL139730 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SERODY, JONATHAN S. · 2017 to 2020
$2.2M
PTEN, Tregs and MDSCs in the tumor microenvironmentR01CA211229 · NCI · AUGUSTA UNIVERSITY · PI MUNN, DAVID H. · 2017 to 2021
$1.7M
CIHRNCI NIH HHS R01 CA103320NCI NIH HHS R01 CA211229NHLBI NIH HHS R01 HL056067NHLBI NIH HHS R01 HL095791NHLBI NIH HHS R01 HL118979NHLBI NIH HHS R01 HL139730NHLBI NIH HHS R37 HL056067NIAID NIH HHS R01 AI034495NIAID NIH HHS R37 AI034495NIAID NIH HHS U19 AI051731
6 · The paper itself

Abstract

Recent studies have underscored the critical role of retinoic acid (RA) in the development of lineage-committed CD4 and CD8 T cells in vivo. We have shown that under acute graft-versus-host disease (GVHD) inflammatory conditions, RA is upregulated in the intestine and is proinflammatory, as GVHD lethality was attenuated when donor allogeneic T cells selectively expressed a dominant negative RA receptor α that blunted RA signaling. RA can function in an autocrine and paracrine fashion, and as such, the host cell lineage responsible for the production of RA metabolism and the specific RA-metabolizing enzymes that potentiate GVHD severity are unknown. In this study, we demonstrate that enhancing RA degradation in the host and to a lesser extent donor hematopoietic cells by overexpressing the RA-catabolizing enzyme CYP26A1 reduced GVHD. RA production is facilitated by retinaldehyde isoform-2 (RALDH2) preferentially expressed in dendritic cells (DCs). Conditionally deleted RA-synthesizing enzyme RALDH2 in host or to a lesser extent donor DCs reduced GVHD lethality. Improved survival in recipients with RALDH2-deleted DCs was associated with increased T cell death, impaired T effector function, increased regulatory T cell frequency, and augmented coinhibitory molecule expression on donor CD4

Indexed as

Aldehyde OxidoreductasesAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDendritic CellsFemaleGene Expression Regulation, EnzymologicGraft vs Host DiseaseMiceMice, Inbred BALB CMice, TransgenicRetinoic Acid 4-HydroxylaseTretinoinAldehyde OxidoreductasesCyp26a1 protein, mouseRALDH2 protein, mouseRetinoic Acid 4-HydroxylaseTretinoin

Identifiers

PMID30885956
PMCPMC6478543
OpenAlexW2920973618

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.